Sanara Medtech Inc
SMTI
View Detailed Chart
34.640USD
+0.450+1.32%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
308.42MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.32%
5 Days
-1.81%
1 Month
+9.69%
6 Months
+2.97%
Year to Date
+4.34%
1 Year
+11.35%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
50.000
Target Price
+42.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 89.06% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 86.67M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 21.76.
Overvalued
The company’s latest PE is -29.47, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 6.82M shares, increasing 6.38% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 175.98K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
Ticker SymbolSMTI
CompanySanara Medtech Inc
CEOMr. Suresh V. (Sam) Muppalla
Websitehttps://sanaramedtech.com/
Related Instruments
+0.37%
-1.73%
+0.54%
-0.80%
-0.14%
+6.29%
+0.49%
+0.41%
+1.21%
+0.35%
+1.51%
-0.01%
-1.26%
-0.31%
-0.17%
-1.49%
-0.03%
+0.11%
+2.26%
+0.10%
